7 completed. 7 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg) - Thyroid Eye Disease | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 38 | 2024-09-04 | 2025-10-03 |
| A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease LASN01, Placebo - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 2 | Completed | Lassen Therapeutics Inc. | 41 | 2024-03-05 | 2026-03-09 |
| Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) lonigutamab, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | ACELYRIN Inc. | 31 | 2023-02-14 | 2025-07-01 |
| A Study of IBI311 in Subjects With Active Thyroid Eye Disease IBI311, placebo - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 115 | 2023-02-14 | 2024-02-08 |
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Linsitinib, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 2 / Phase 3 | Completed | Sling Therapeutics, Inc. | 90 | 2022-07-01 | 2026-09-23 |
| A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | Lassen Therapeutics 1 PTY LTD | 75 | 2022-06-06 | 2024-12-30 |
| Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease peri-levator betamethasone injection, peri-levator triamcinolone injection, peri-levator and retrobulbar betamethasone injection - Thyroid Eye Disease | Phase 2 / Phase 3 | Completed | Assiut University | 92 | 2021-12-01 | 2023-11-14 |
Graves Ophthalmopathy (7) · Endocrine System Diseases (2) · Exophthalmos (2) · Eye Diseases (2) · Orbital Diseases (2) · Hashimoto Disease (1) · Pulmonary Fibrosis (1) · Thyroid Diseases (1)
Autoimmune Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Eye Diseases, Hereditary (7) · Genetic Diseases, Inborn (7) · Goiter (7) · Graves Disease (7) · Hyperthyroidism (7) · Immune System Diseases (7) · Thyroid Diseases (6) · Endocrine System Diseases (5) · Exophthalmos (5) · Eye Diseases (5) · Orbital Diseases (5) · Fibrosis (1) · Lung Diseases (1)
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1)
Innovent Biologics (Suzhou) Co. Ltd. (2) · ACELYRIN Inc. (1) · Assiut University (1) · Lassen Therapeutics 1 PTY LTD (1) · Lassen Therapeutics Inc. (1) · Sling Therapeutics, Inc. (1)
United States (3) · Australia (2) · China (2) · Spain (2) · United Kingdom (2) · Canada (1) · Egypt (1) · Hong Kong (1) · Italy (1)
Ahmed Abdelal, MD (1) · Mohamed Shehata, MD (1) · Salma Kedwany, MD (1)